China Resources Double-Crane Pharmaceutical Co.,Ltd.

XSSC:600062 Stock Report

Market Cap: CN¥20.1b

China Resources Double-Crane PharmaceuticalLtd Management

Management criteria checks 1/4

China Resources Double-Crane PharmaceuticalLtd's CEO is Wenchao Lu, appointed in Jul 2024, has a tenure of less than a year. directly owns 0.024% of the company’s shares, worth CN¥4.84M. The average tenure of the management team and the board of directors is 2 years and 2.7 years respectively.

Key information

Wenchao Lu

Chief executive officer

CN¥2.3m

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.02%
Management average tenure2yrs
Board average tenure2.7yrs

Recent management updates

Recent updates


CEO

Wenchao Lu (47 yo)

less than a year

Tenure

CN¥2,319,500

Compensation

Mr. Wenchao Lu is Chairman of the board of China Resources Double-Crane Pharmaceutical Co. Ltd. from September 21, 2023 and serves as its Acting President since July 2024. Mr. Lu was President of China Res...


Leadership Team

NamePositionTenureCompensationOwnership
Wenchao Lu
Chairman of the Board & Acting Presidentless than a yearCN¥2.32m0.024%
CN¥ 4.8m
Hekai Tan
VP & Company Secretaryno dataCN¥1.11m0.014%
CN¥ 2.8m
Ziqin Liu
Vice President4yrsCN¥1.60m0.018%
CN¥ 3.6m
Chao Man
Vice President4yrsCN¥1.80m0.025%
CN¥ 5.1m
Donghan Yao
Vice President2yrsCN¥923.00kno data
Ju Liu
Chief Financial Officerless than a yearno datano data

2.0yrs

Average Tenure

49yo

Average Age

Experienced Management: 600062's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Wenchao Lu
Chairman of the Board & Acting President2.5yrsCN¥2.32m0.024%
CN¥ 4.8m
Xiangming Li
Director3.3yrsno datano data
Ning Liu
Independent Director3.6yrsCN¥150.00kno data
Maozhu Sun
Independent Director3.6yrsCN¥150.00kno data
Na Tang
Chairman of the Supervisory Board3.6yrsno datano data
Lili Yan
Employee Supervisor8.4yrsno datano data
Xiaosong Bai
Director2.9yrsno datano data
Shutian Yu
Director2.2yrsno datano data
Hui Xu
Director1.3yrsno datano data
Guolong Lin
Director1.3yrsno datano data
Zhen Chen
Independent Directorless than a yearno datano data
Qiansheng Zhao
Director1.1yrsno datano data

2.7yrs

Average Tenure

56yo

Average Age

Experienced Board: 600062's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/11 15:21
End of Day Share Price 2025/02/11 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

China Resources Double-Crane Pharmaceutical Co.,Ltd. is covered by 19 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhi Xue DiaoAvic Securities Co., Ltd
Jessica LiBofA Global Research
Helena QiuCCB International Securities Limited